Antengene Corp

Antengene Corp Current Liabilities

The Current Liabilities of Antengene Corp (6996.HK) as of Oct 31, 2026 is 307.50 M CNY. In the previous year, Current Liabilities was 194.12 M CNY — a change of 58.41% (higher).

Current Liabilities

307.50 MCNY

YoY

58.41%

Last updated:

Current Liabilities of Antengene Corp is 2025 307.50 M CNY. Current Liabilities of Antengene Corp was 2024 194.12 M CNY. It decreases by 58.41% higher compared to the previous year.

The Antengene Corp Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
54.59 M CNY
Jan 1, 2019
482.50 M CNY
Jan 1, 2020
170.99 M CNY
Jan 1, 2021
252.50 M CNY
Jan 1, 2022
513.76 M CNY
Jan 1, 2023
214.22 M CNY
Jan 1, 2024
194.12 M CNY
Jan 1, 2025
307.50 M CNY
The Antengene Corp Current Liabilities history
YEARCurrent LiabilitiesYoY
307.50 MCNY+58.41%
194.12 MCNY-9.38%
214.22 MCNY-58.30%
513.76 MCNY+103.47%
252.50 MCNY+47.67%
170.99 MCNY-64.56%
482.50 MCNY+783.88%
54.59 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Antengene Corp Stock analysis

What does Antengene Corp do? Antengene Corp. Ltd. generates revenue through the development and commercialization of biopharmaceutical products, primarily targeting cancer treatments. The company focuses on ATG-010 (selinexor), which is used for relapsed/refractory multiple myeloma, diffuse large B-cell lymphoma, and non-small cell lung cancer, and ATG-008 (onatasertib), indicated for hepatocellular carcinoma and non-small cell lung cancer. These products are developed for the Asia-Pacific market, where the company conducts its main operations. The firm's revenue streams are derived from the clinical-stage development and eventual commercialization of these therapies, targeting healthcare providers and patients in the region. The company operates as a clinical-stage biopharmaceutical entity, emphasizing discovery, development, manufacturing, and commercialization of innovative cancer treatments. Its primary products, ATG-010 and ATG-008, are designed to address specific oncology indications, with a focus on relapsed or refractory conditions. The Asia-Pacific market serves as the core geographic segment for its business, where it aims to establish a strong presence through its pipeline of biotech products. Revenue is anticipated once these therapies advance through clinical trials and receive regulatory approvals for commercial use. Antengene Corp. Ltd. targets healthcare systems and oncology specialists in the Asia-Pacific region for its biopharmaceutical products. The company’s products are positioned for treatment of complex cancer types, with ATG-010 addressing multiple myeloma and lymphoma, and ATG-008 targeting liver and lung cancers. As a clinical-stage company, its current focus is on advancing these therapies through development stages, with commercialization expected to drive future revenue. The Asia-Pacific market remains central to its business strategy, where it leverages its regional presence to build partnerships and market access. Antengene Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Antengene Corp stock

Current Liabilities of Antengene Corp is 307.50 M CNY in 2025.

Current Liabilities of Antengene Corp changed from 194.12 M CNY to 307.50 M CNY, representing a 58.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Antengene Corp since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Antengene Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Antengene Corp

All Key Metrics — Antengene Corp